Helperby Therapeutics’ Combination Antibiotic Therapy is Effective Against WHO Critical Priority Pathogen in Phase I Study

Helperby Therapeutics has announced Phase I results on the tolerability, pharmacokinetics, pharmacodynamics and efficacy of AZT and colistin both alone and as a combined therapy, against multi-drug resistant Enterobacteriaceae (CRE), one of the most serious drug resistant pathogens.

Click here to read the full paper

---